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Introduction 
Chemicals with direct immunotoxic characteristics may cause a risk to human health, as 
humans can be exposed to these chemicals via food, drinking water, and the environment. 
These direct immunotoxic properties are evaluated in the safety assessment of new and 
existing chemicals and food additives (EPA 1998; Institóris et al. 1998), and during the 
preclinical phase of pharmaceutical development (EMA 2000; FDA 2002). Currently, 
immunotoxicity tests are mainly based on changes in organ weights in animal experiments, 
histopathology of those organs (spleen, thymus, bone marrow, lymph nodes) or by 
measuring serum parameters (FDA 2002). Disadvantages of animal tests are related to the 
high costs and long time needed as well as to ethical issues (Corsini and Roggen 2009). In 
addition, animal studies rely mostly on apical endpoints, do not sufficiently yield insights 
into the molecular mechanisms of direct immunotoxicity and often have limited prediction 
towards the human situation. Thus, animal free alternatives are urgently needed. The latter 
is a key element in a report from the National Research Council (NRC) of the U.S. National 
Academy of Science entitled “Toxicity testing in the 21st Century: A Vision and A 
Strategy”(2007). In this report, the NRC supports the shifts from animal testing to 
(preferably human-based) in vitro testing and from single endpoint studies to studies 
addressing toxicity pathways. This support for omics approaches in defining new endpoints 
was also shared by the European Centre for the Validation of Alternative Methods 
(ECVAM) (Bouvier d'Yvoire et al. 2012). The application of transcriptomics provides 
mechanistic insights into the mode of action of the chemical and can also yield biomarkers 
that represent a specific toxicological endpoint.  
Innovation and social relevance of the research results 
Recently, in vitro transcriptomics studies using human and rodent T cell lines and primary 
cells have led to a better insight into the mechanism of action of a limited set of 
immunotoxicants. The question which of the available models would be most suitable to 
screen compounds for immunotoxicity was however not yet answered. Therefore, the work 
described in the present thesis started with a comparative assessment of several models 
using three different model immunotoxicants (CsA, TBTO and DON). As it became 
apparent that the in vitro mouse models (CTLL-2 and EL-4 cell lines) as compared to the 
human Jurkat T cell line lacked some important features to detect the immunotoxicity of 
these immunotoxicants, a larger set of chemicals was studied by using the human Jurkat T 
cell line. These studies were performed by colleagues and resulted in the identification of a 
set of mechanism-based biomarkers that allowed to distinguish immunotoxicants from non 
immunotoxicants with a relatively high accuracy 85%. As some questions remained 
unanswered, such as: “How does this model perform when challenged with chemicals that 
were not tested before?” the set of biomarkers was further tested with a new set of 
compounds in this thesis. This additional pre-validation of the biomarkers resulted in 
excellent sensitivity (100%), specificity (80%) and accuracy (93%). In addition, the 
immunotoxicity of chemicals originating from classes that were not tested before could also 
be confirmed. It was concluded that the Jurkat T cell model in combination with the 
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biomarker gene set promises to be a useful module within a battery of tests to screen new 
and existing chemicals for immunotoxicity. Besides assessments on immunotoxicity of 
chemicals, one study was set up using known immunotoxicants in one microarray 
experiments. This allowed a direct comparison between the gene expression profiles of 
compounds with suspected similar modes of action.  
Taken together, the results of this thesis showed that of the models assessed, the Jurkat T 
cell line gave the best prediction for immunotoxicity testing. Using this cell line in a 
toxicogenomics setting resulted in valuable mechanistic information and biomarkers for 
immunotoxicity were pre validated in a second experiment with another set of 
immunotoxicants and non-immunotoxicants. The research performed was in line of the 
framework of US NRC, US FDA and ECVAM contributing to the development of animal 
free screening models. 
Concrete product 
The set of biomarkers that were pre-validated in this thesis can be used in a high-throughput 
setting allowing screening of large sets of chemicals in a short time. In the present thesis a 
Fluidigm high-throughput PCR system was used, however, other possibilities exist. 
Biomarkers could also be tested using a Luminex setting, which has the advantage that the 
quantification of mRNA is done directly on  lysates of cultured cells, so no RNA isolation 
and purification steps are required (Zheng et al. 2006). Though this makes the Luminex 
system more high throughput, the Fluidigm setting is fast, cheaper than the Luminex 
system, and has already proven itself in Jurkat immunotoxicity experiments.  
Potential applications 
An assay that is created on the basis of the outcome of this thesis can be used for several 
purposes. First, it can be used within drug development to screen for potential immunotoxic 
properties of newly developed pharmaceuticals. Second, within the framework of REACH, 
an assay could be used in the safety evaluation of existing chemicals and the presence of 
immunotoxicants in food, feed and water.  
 
Implementation schedule 
The present thesis proved the value of the identified biomarkers, however, some 
improvements are still to be investigated. To generate a more powerful validation, more 
non-immunotoxicants need to be used in this screening set up to balance the large number 
of known immunotoxicants with the low number of known non-immunotoxicants. A next 
step will be the submission of the results of the Jurkat screening assay to ECVAM for 
independent further validation. Because the cell line (Jurkat T cell line) and the primers in 
RT-PCR (Taqman) are both commercially available, this will shorten the time for 
validation by ECVAM. Parallel to this, similar exercises as done in this thesis could be 
performed for other immune cell lines, such as a macrophage cell line or a Natural Killer 
cell line. When compounds can be screened in three cell lines (T cell, NK and macrophage) 
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with the same set of biomarkers, this will increase the power of the assay, as immunotoxic 
chemicals might specifically affect NK cells or macrophages and do not affect T cells.  
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